Chipmakers, Sanofi deal dominate European share trading
Reuters
Published Jan 29, 2018 03:52AM ET
Chipmakers, Sanofi deal dominate European share trading
LONDON (Reuters) - Stellar results from chipmaker AMS and another big pharma deal dominated European share trading at the start of a heavy earnings week.
The euro, whose strength had crimped stocks late last week, eased back from its highs, helping Europe's STOXX 600 index (STOXX) inch up 0.1 percent, while euro zone stocks (STOXXE) stayed flat, with most of the activity under the benchmark level.
Austria's AMS (S:AMS) soared 25 percent after its 2017 revenue doubled and the iPhone component supplier raised its growth forecasts far beyond analyst expectations.
Peers Dialog Semiconductor (DE:DLGS), STMicro (MI:STM), and Infineon (DE:IFXGn) all rose, gaining between 1.1 and 5 percent, led by Dialog, whose shares have tumbled since late November.
Sanofi (PA:SASY) muscled Novo Nordisk (CO:NOVOb) out of the way to buy Ablynx (BR:ABLX), clinching a 3.9 billion euro deal for the Belgian biotech firm.
The French pharma giant's shares were down 0.3 percent as traders digested the hefty price tag of 45 euros per share, against Ablynx's closing price of 39 euros on Friday. The offer was a 109 percent premium to Ablynx's share price prior to Novo Nordisk's bid on Jan 8.
Ablynx shares were suspended from trading until 1030 local time (0930 GMT), the Belgian market regulator said.
Shares in Swedish medical technology group Getinge (ST:GETIb) sank 8.4 percent to the bottom of the STOXX after it reported fourth-quarter profit far below market forecasts, and said 2018 results would be affected by currency transactions.
Overall, European stocks kept a decisive cyclical tilt, with miners, autos, financial services and tech all gaining while utilities, food and beverage and real estate stocks slipped.
Spain's Enagas (MC:ENAG) fell 3.8 percent after Kepler Cheuvreux cut its target price on the stock.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.